Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...

MaxCyte ( NASDAQ: MXCT) Wednesday said that it had entered into a strategic platform license with TG Therapeutics, a fully integrated, commercial-stage, biopharmaceutical company focused on the ...

MaxCyte (MXCT) announced they are entering into a strategic platform license with TG Therapeutics (TGTX). Under the terms of the agreement, TG ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherap ...

Deepgram, the leading voice AI platform for enterprise use cases, today announced the launch of Nova-3, its most advanced speech-to-text (STT) model to date. Nova-3 pushes the boundaries of AI-driven ...